Asset profile
HTI vaccine (ChAdOx1.HTI/MVA.HTI)
Vaccine
Evidence outlook · lead readout
NCT04364035 · HIV/AIDS
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04364035: The study randomized 50 participants to vaccine-plus-vesatolimod or placebo and used quadruple blinding, with primary endpoints measuring Grade 3 or 4 reactions and serious adverse events. Because the registry has no posted results, whether the primary endpoints were met or missed is unknown, supporting a moderate evidence grade rather than a strong one.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.